Pre-treatment of the CLL cells with JNK inhibitor SP600125 abrogated the P1446A-mediated effects on NOXA, while PUMA transcript levels were not affected (Fig 5B and 5C), suggesting that NOXA upregulation is JNK-dependent in this setting. The gene discussed is BBC3; the disease is B-cell chronic lymphocytic leukemia.